GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The free fatty acid receptor GPR40 has been proposed as a potential target for type 2 diabetes ( T2D ) pharmacotherapy. This idea has been validated in both preclinical and clinical studies, in which activation of GPR40 was shown to improve glycaemic control by stimulating glucose‐dependent insulin secretion; however, the recent termination of phase III clinical trials using the GPR40 agonist TAK ‐875 (fasiglifam) has raised important questions regarding the long‐term safety and viability of targeting GPR40 and, more specifically, about our understanding of this receptor's basic biology. In the present review, we provide a summary of established and novel concepts related to GPR40 's pharmacobiology and discuss the current status and future outlook for GPR40 ‐based drug development for the treatment of T2D .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 10×
“The reasons for TAK-875’s hepatotoxic effects remain unknown; however, GPR40 does not appear to be expressed in the liver [4,5], suggesting that it is probably an indirect phenomenon not related to direct hepatic activation of GPR40.”
BackgroundResultInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · cited 1×
“Part of this effect has been attributed to GPR40-mediated signaling, as evidenced by the expression of GPR40 in enteroendocrine cells [62–65] and the observed reduction of plasmatic incretin levels in GPR40 KO mice after lipid ingestion [62,64,65].”
BackgroundMetabolic Signaling in Fuel-Induced Insulin Secretion
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.018 · Cited by 548 · cited 4×
“FFAs can also enter the mitochondria for β-oxidation or serve as substrates for lipogenesis (MAG → DAG → TAG), resulting in the generation of coupling factors implicated in insulin secretion [8].”
BackgroundInfluentialWang, Z., & Thurmond, D. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.034355 · Cited by 386 · cited 1×
“It is believed that first-phase insulin secretion corresponds to the exocytosis of a readily-releasable pool of insulin granules pre-docked at the plasma membrane, whereas the second phase relies on the mobilization of an intracellular granule pool to the plasma membrane via a process that requires cytoskeletal remode…”
BackgroundGlucolipotoxicity of the pancreatic beta cell
Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D., & Fontés, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.08.006 · Cited by 382
Self-citationParker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324
Fujiwara, K., Maekawa, F., & Yada, T. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2005 · Cited by 253
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244 · cited 3×
“trials [39,40] in participants with T2D showed that treatment with TAK-875 enhanced insulin secretion and reduced glycated haemoglobin (HbA1c) levels by 1.”
BackgroundRole of GPR40 in fatty acid action on the β cell line INS-1E
Shapiro, H., Shachar, S., Sekler, I., Hershfinkel, M., & Walker, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.042 · Cited by 220
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Therapeutic potential of ectopic olfactory and taste receptors
Lee, S.-J., Depoortere, I., & Hatt, H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0002-3 · Cited by 279
Complex Pharmacology of Free Fatty Acid Receptors
Milligan, G., Shimpukade, B., Ulven, T., & Hudson, B. D. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00056 · Cited by 267
Never waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“It has been shown that CXCL17 causes the migration of macrophages from the lungs of wild-type mice, but not from Cxcl172/2 mice, indicating a role in inflammation (Maravillas-Montero et al., 2015).”
Metadata
- Authors
- Mancini, A. D., & Poitout, V.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-02-24
- Volume
- 17
- Issue
- 7
- Pages
- 622-629
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1979400849
- Cited by
- 99
- References
- 14
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit. https://app.cochat.ai/papers/10.1111/dom.12442
- The paper
- Mancini, A. D., & Poitout, V. (2015). GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.